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Objectives 
The aim of this study was to investigate the impact of cardiac resynchronization therapy 
(CRT) on right ventricular (RV) function and the influence of RV dysfunction on the 
echocardiographic and clinical response to CRT among patients enrolled in the CARE-HF 
(Cardiac Resynchronization-Heart Failure) trial. 
Background 
Cardiac resynchronization therapy prolongs survival in appropriately selected patients with 
heart failure but the benefit might be diminished in patients with RV dysfunction. 
Methods 
Of 813 patients enrolled in the CARE-HF study, 688 had tricuspid plane systolic excursion 
(TAPSE) measured at baseline, and 345 of these were assigned to CRT. Their median 
(interquartile range) age was 66 (58 to 71) years, left ventricular (LV) ejection fraction was 
24% (21% to 28%), and TAPSE was 19 (16 to 22) mm. Baseline LV function and size and 
QRS duration were similar among TAPSE tertiles, but those in the worst tertile (TAPSE 
<17.4 mm) were more likely to have ischemic heart disease. 
Results 
Overall, CRT improved LV but not RV structure and function with little evidence of an 
interaction with TAPSE. During a median (interquartile range) follow-up of 748 (582 to 950) 
days, 213 deaths occurred. Patients with lower TAPSE had a higher mortality, regardless of 
assigned treatment (p < 0.001). Greater inter-ventricular mechanical delay, New York Heart 
Association functional class, mitral regurgitation, and N-terminal pro–B-type natriuretic 
peptide, lower TAPSE, and assignment to the control group were independently associated 
with higher mortality. Reduction in mortality with CRT was similar in each tertile of TAPSE. 
Conclusions 
Right ventricular dysfunction is a powerful determinant of prognosis among candidates for 
CRT, regardless of treatment assigned, but did not diminish the prognostic benefits of CRT 
among patients enrolled in the CARE-HF trial. (Care-HF CArdiac Resynchronization in 
Heart Failure; NCT00170300) 
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Right ventricular (RV) dysfunction indicates a poor prognosis in patients with heart failure 
(1 and 2). Cardiac resynchronization therapy (CRT) improves left ventricular (LV) function, 
symptoms, and prognosis in patients with symptomatic heart failure, LV systolic dysfunction, 
and a prolonged QRS duration (3). However, uncertainty exists both about the effects of CRT 
on RV function (4, 5, 6, 7, 8 and 9) and how RV dysfunction affects the response to CRT (4, 
5, 6, 7, 8, 9 and 10). However, observational studies measure outcome with but not the 
response to an intervention. A control group is required to distinguish treatment effects from 
the natural history of the disease (11). A post-hoc analysis of the REVERSE 
(REsyncronization reVErses Remodeling in Systolic left vEntricular dysfunction) trial, 
including 450 patients with chronic heart failure and mild symptoms, suggested that those 
with RV dysfunction (tricuspid annular plane systolic excursion [TAPSE] ≤14 mm) had a 
diminished response to CRT (n = 61), with less reverse LV remodelling and a poorer 
symptomatic response (12). 
We investigated the impact of CRT on RV function and the influence of RV dysfunction on 
the echocardiographic and clinical response to CRT among patients enrolled in the CARE-HF 
(Cardiac Resynchronization−Heart Failure) trial (13). 
Methods 
The CARE-HF trial was a randomized trial of 813 patients (3) who had symptoms of heart 
failure despite guideline-indicated treatment who were in sinus rhythm and had LV systolic 
dysfunction and dilation and markers of cardiac dyssynchrony. 
This analysis is based on 688 patients (85% of all patients in the CARE-HF trial) who had a 
measurement of lateral wall TAPSE at baseline by M-mode (13). In addition to TAPSE, 
echocardiographic measurements included: LV end-diastolic and end-systolic volumes, left 
ventricular ejection fraction (LVEF), RV end-diastolic area and end-systolic area, RV 
fractional shortening area, mitral regurgitation and tricuspid regurgitation (TR) by measuring 
the area of the jet divided by the area of the right atrium on color flow Doppler and trans-
tricuspid gradient pressure. Echocardiography was repeated at 3, 9, and 18 months. 
Statistical methods 
Continuous data were summarized by the median (25th/75th) percentiles; categorical data 
were summarized by percentages. An analysis of variance model was used to look at the 
trend for continuous variables; the chi-squared test was used to look for trend for categorical 
variables (Table 1 and Table 2). Data are shown by tertile of TAPSE. The primary outcome 
measure of the CARE-HF trial was all-cause mortality or an unplanned hospital stay for a 
major cardiovascular event. All-cause mortality was the principal secondary endpoint and the 
primary endpoint of an extension phase (3). 
Survival curves were constructed with the Kaplan-Meier method; univariate and multivariate 
Cox regression modeling were performed to assess the independent impact of TAPSE on 
clinical outcome (14 and 15). We explored whether the inclusion of 3 additional covariates—
TAPSE, TR jet/right atrial diastolic area, and TR pressure gradient—added prognostic value 
to previous models (14 and 15). Both baseline and 3-month post-implant values were 
considered. Where the proportional hazards assumption was violated, Cox models with time-
dependent effects were considered. Over-fitting and goodness-of-fit was also addressed. 
Missing values at 3 months were imputed from baseline values to preserve the integrity of 
randomization. 
Results 
The maximum and minimum values for TAPSE in each tertile were 5.5 to 17.3 mm, 17.4 to 
21.1 mm, and 21.2 to 33.4 mm, respectively; 93 patients had values ≤14 mm. Patients in the 
lowest tertile of TAPSE were more often men, were twice as likely to have ischemic heart 
disease (IHD), and had evidence of more severe heart failure (Table 1). 
Cardiac resynchronization therapy reduced LV end-systolic and -diastolic volumes and 
increased LVEF within 3 months of implantation, with evidence of further benefit by 9 
months, which was sustained at 18 months (16). Mitral regurgitation was reduced by 3 
months, and the effect was sustained (Table 2). Overall, CRT did not improve RV structure 
and function. The effects of CRT on LV structure and function and mitral regurgitation and 
the lack of effect on RV structure and function were broadly similar across tertiles of TAPSE, 
although patients in the worst tertile had a slightly greater reduction in RVES area and TR 
gradient (Table 2). Results for RV structure and function were similar when patients were 
divided according to the presence or absence of IHD (Fig. 1). 
 
Figure 1.  
Among patients with a TAPSE measurement, 329 reached the primary endpoint (T1 = 145, 
T2 = 99, T3 = 85), and 213 died (Fig. 2). The median (interquartile range) follow-up, 
censored for death, was 748 days (58 to 950) days. A higher TAPSE at baseline was 
associated with a lower risk of the primary outcome (chi-square log-rank test: 27.1; p < 
0.001) and better survival (chi-square log-rank test: 12.4; p < 0.001), regardless of treatment 
assigned. However, the effect of CRT on outcome was similar across tertiles of TAPSE (Figs. 
2A and 2B). Analysis confined to the 93 patients with a TAPSE ≤14 mm also showed similar 
improvement in outcome, both for the primary endpoint (hazard ratio: 0.57, 95% confidence 
interval: 0.34 to 0.94, p = 0.029) and all-cause mortality (hazard ratio: 0.62, 95% confidence 
interval: 0.34 to 1.11, p = 0.11). Patients with worse TAPSE were more likely to die of heart 
failure. Caution should be applied to interpretation of CRT effects on mode of death in 
subgroups, due to the small number of events (Fig. 2B). 
 
Figure 2.  
 
Adding measures of RV function to a published multivariable model (14) eliminated IHD as 
a predictor of mortality, replacing it with TAPSE measured at 3 months after randomization 
(Table 3). The following variables, as in the original published model, remained 
independently associated with higher all-cause mortality: less interventricular mechanical 
delay at baseline; New York Heart Association functional class IV at baseline; assignment to 
the control group; more severe mitral regurgitation at 3 months; and higher N-terminal pro–
B-type natriuretic peptide at 3 months (14) (Table 3). The model did not suffer from over-
fitting (17). The proportional hazards assumption was not violated (overall chi-square test = 
4.2, df = 6, p = 0.64) ( 18). In univariate analyses, LV volumes and LVEF measured at 3 
months were more strongly related to prognosis than measurements at baseline, but none 
contributed independent prognostic information on a multivariable analysis. 
Discussion 
This analysis shows that CRT has little effect on RV function and that the severity of RV 
dysfunction is a weak determinant of the effects of CRT on LV structure or function. 
Although a marker of a worse overall prognosis, RV dysfunction was not an important 
determinant of the relative benefits of CRT. 
As far as we are aware, this is the first study to investigate the effect of CRT on RV function 
in a randomized controlled trial. Cardiac resynchronization therapy might be expected to 
improve RV function by lowering left atrial and pulmonary artery pressures due to 
improvements in LV function and mitral regurgitation (19, 20, 21 and 22). However, pacing 
leads might interfere with tricuspid valve function and RV apical pacing might impair RV 
function (23). However, we identified no substantial improvement in right heart function with 
CRT when compared with pharmacological therapy alone, in contrast to several (7 and 19), 
but not all (24), observational studies, although we might have missed subtle changes that can 
be measured by newer echocardiographic techniques, such as tissue Doppler or RV strain 
(24 and 25). 
At baseline, LV systolic dysfunction was similar across tertiles of TAPSE, but those with 
worse TAPSE had more severe mitral regurgitation, higher pulmonary artery pressure, more 
severe TR and higher plasma concentration of N-terminal pro–B-type natriuretic peptide. The 
extent to which RV dysfunction reflects pulmonary hypertension or intrinsic RV dysfunction 
is uncertain and likely to vary over time and among individual patients (26). However, the 
high prevalence of IHD in patients with worse TAPSE suggests that RV ischemic damage 
might be common (7, 19, 20, 21, 22, 24, 25 and 26). Poor baseline RV function was 
associated with a trend to smaller improvements in LV function in response to CRT, 
consistent with a previous report (12). However, this trend was accounted for by the high 
prevalence of IHD in patients with RV dysfunction. Patients with IHD are more likely to 
have myocardial scar, which will impair the beneficial remodeling response to both 
pharmacological interventions and CRT (27 and 28). 
There is growing evidence, reinforced by this analysis, that RV rather than LV dysfunction 
might be the more important determinant of prognosis (1 and 26). Both lower TAPSE and 
higher TR gradient estimated at baseline were associated with an adverse prognosis, and this 
relationship was strengthened when re-estimated at 3 months after randomization. 
Interestingly, after measures of RV dysfunction were added to the prognostic model, the 
presence of IHD was no longer an independent predictor of outcome. This could also reflect 
the importance of RV damage due to ischemia (29). Whether, RV dysfunction or etiology is 
the more important driver of an adverse prognosis is uncertain. The strong statistical 
association between worse TAPSE and higher prevalence of IHD suggests that one might just 
be a surrogate for the other in such models. 
Several observational (6 and 10) studies have suggested that patients with RV dysfunction 
receive less prognostic benefit from CRT. The problem with observational studies is that they 
are unable to distinguish between outcome with treatment and response to it (11). This 
analysis confirms previous reports showing that, in patients who receive CRT, those with 
poor RV function will have a worse outcome. However, the change in prognosis (i.e., the 
response to treatment) is similar in patients with and without RV dysfunction. This 
contradicts assertions that CRT is ineffective in patients with substantial RV dysfunction 
(6 and 10). Whether the severity of RV dysfunction should influence the choice between 
CRT and CRT with defibrillator is uncertain. Patients with RV dysfunction are more likely to 
die of heart failure rather than suddenly. However, sudden death still represents a substantial 
proportion of deaths in patients with RV dysfunction, which might be reduced by 
implantation of CRT with defibrillator. 
Study limitations 
The current hypothesis was not defined prior to conducting the study. Ideally, the results 
should be confirmed in a prospective trial of patients with both RV and LV dysfunction, but 
it is not clear whether this would receive ethical clearance. Alternatively, data might be 
available from another randomized trial that could be analyzed, retrospectively. A study of 
the size and duration of the CARE-HF trial is unlikely to have missed substantial effects of 
CRT on RV function but more modern imaging technologies might identify subtler effects. 
On the other hand, the study was not adequately powered to investigate the effects of CRT on 
outcomes, such as mode of death in subgroups of patients. 
Conclusions 
Right ventricular dysfunction is a powerful determinant of prognosis among candidates for 
CRT, regardless of treatment assigned, but does not diminish the prognostic benefits of CRT 
among patients enrolled in the CARE-HF trial. 
These data illustrate the difference between “outcome with” and “response to” CRT, urging 
caution in the interpretation of observational data, and might help clinicians make appropriate 
clinical choices for their patients. 
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Table 1.     
        Clinical<comma> Biological<comma> and Echocardiography Characteristics at Baseline in Entire Population and 
Divided by Tertiles of TAPSE 
Baseline Characteristics TAPSE Tertiles (n = 688)  
T1 (n = 233) T2 (n = 231) T3 (n = 224) p Value for Trend 
Clinical     
Age<comma> yrs 66(60–73) 58(51–66) 65(57–71) 0.07 
Men 195(84) 150(65) 155(69) <0.001 
NYHA functional class IV 15(6) 16(7) 11(5) 0.5 
BMI (kg/m2) 25(23–28) 26(23–29) 27(24–30) 0.001 
Heart rate<comma> 
beats/min 
71(62–83) 68(60–77) 69(60–76) 0.01 
Systolic BP<comma> 
mm Hg 
110(100–120) 117(105–130) 120(110–130) <0.001 
LBBB 206(88) 207(89) 206(91) 0.05 
QRS duration (ms) 160(150–180) 165(154–180) 160(152–180) 0.87 
Ischemic heart disease 121(52) 65(28) 44(20) <0.001 
NT-proBNP (pg/ml) 3<comma>023(1<comma>310–
5<comma>979) 
1<comma>792(727–
4<comma>287) 
1<comma>099(566–
2<comma>740) 
<0.001 
eGFR<comma> 
ml/min/1.73 m2 
53(42–67) 59(43–72) 64(49–77) <0.001 
Echocardiography    
LVEDV (ml) 296(246–354) 307(237–384) 295(235–385) 0.82 
LVESV (ml) 225(180–273) 222(168–294) 219(167–290) <0.001 
LVEF (%) 23(20–26) 24(21–29) 25(22–29) <0.001 
LA diastolic area 23(18–29) 19(14–23) 18(15–24) <0.001 
MR jet area (mm2) 25(15–35) 23(13–32) 16(9–30) <0.001 
IVMD<comma> ms 46(26–64) 48(33–65) 51(31–72) 0.034 
RVED area<comma> 
cm2 
23(18–29) 20(16–24) 19(16–22) <0.001 
RVES area<comma> 
cm2 
16(10–20) 11(8–14) 10(7–13) <0.001 
RV fractional shortening 
area<comma> % 
31(23–40) 43(36–50) 47(38–54) <0.001 
TAPSE<comma> mm 14(12–16) 19(18–20) 23(22–25) <0.001 
TR jet area<comma> 
cm2 
3.4(1.8–6.4) 2.2(1.3–4.0) 1.8(1–3) <0.001 
TR jet available 179(77) 160(69) 137(61) <0.001 
RA diastolic 
area<comma> cm2 
16.2(10.8–21.4) 11(8.9–14.7) 10.5(8.8–13) <0.001 
TR jet area/RA area cm2 21.9(15.2–33.6) 18.9(12.5–29.6) 15.3(10.4–25.9) <0.001 
TR gradient<comma> 
mm Hg 
33(24–42) 28(21–36) 28(21–37) 0.011 
TR gradient available 141(60) 124(53) 79(37) <0.001 
Treatment    
Beta-blockers 164(70) 164(70) 172(77) 0.12 
ACE inhibitors/ARB 220(94) 219(94) 212(94) 0.91 
Aldosterone inhibitor 131(56) 129(55) 125(55) 0.92 
Furosemide ≥80 mg/day 134(57) 89(38) 68(30) <0.001 
Digitalis 91(39) 96(41) 109(48) 0.039 
 
 
Values are median (25th/75th percentiles) or n (%). 
ACE = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index; BP = blood 
pressure; eGFR = estimated glomerular filtration rate; IVMD = interventricular mechanical delay; LA = left atrial; LBBB = left 
bundle branch block; LVEDV = left ventricular end-diastolic volume; LVESV = left ventricular end-systolic volume; MR = mitral 
regurgitation; NT-proBNP = N-terminal pro–B-type natriuretic peptide; NYHA = New York Heart Association; RA = right atria; 
RV = right ventricle; RVED = right ventricular end-diastolic area; RVES = right ventricular end-systolic area; TAPSE = tricuspid 
annular plane systolic excursion; TR = tricuspid regurgitation. 
 
Table 2.          
        Changes in Quality of Life and Cardiac Function Between Baseline and 9 Months  
TAPSE Tertiles T1 T2 T3 p Value      
CRT Medical CRT Medical CRT Medical Control 
vs. CRT 
Interaction TAPSE 
vs. CRT 
Number with 
paired results 
89 75 94 92 85 93    
LVEDV (ml) −27(−67t
o−3) 
−1(−29to
15) 
−59(−98t
o−22) 
−11(−39t
o7) 
−49(−10
7to−6) 
−6(−38to
16) 
<0.0
01 
0.11  
LVESV (ml) −30(−66t
o−10) 
−7(−30to
11) 
−60(−95t
o−19) 
−11(−32t
o7) 
−46(−96t
o−12) 
−9(−37to
9) 
<0.0
01 
0.15  
LVEF (%) 4(1.3to9.
2) 
0.9(−0.9t
o3.2) 
5.6(1.1to
10.8) 
1(−1.7to3
.7) 
6.2(1.6to
11.9) 
1.2(−0.7t
o4.2) 
<0.0
01 
0.12  
LA diastolic 
area<comma> 
cm2 
−4.8(−8.4
to1.8) 
−3.7(−7.1
to2.2) 
−3.8(−7.7
to0.6) 
−1.9(−7.0
to1.7) 
−5.2(−9.
2.07) 
−2.4(−3.7
to0.8) 
0.01 0.24  
MR jet area (%) −4(−13to
−2) 
0(−11to9) −4(−14to
1) 
0(−9to5) −3(−9to3
) 
2(−3to10) 0.00
1 
0.22  
IVMD (ms) −24(−41t
o−4) 
0(−17to1
5) 
−21(−38t
o−9) 
−5(−21to
10) 
−24(−40t
o−2) 
1(−9to13) <0.0
01 
0.13  
TAPSE (mm) 1.1(−0.1t
o3.7) 
1.4(−0.7t
o4.1) 
0.4(−.1to
3.6) 
0.8(−1.1t
o2.8) 
−1.0(−3.
5to0.1) 
−.2.1(−3.
6to0.8) 
0.5 0.79  
RVED area (cm2) −1(−7.4to
1.1) 
−0.1(−3.1
to2.5) 
−0.9(−3.7
to1.4) 
−1.6(−3.4
to0.7) 
−1.2(−3.
5to0.7) 
−0.9(−3.5
to2.0) 
0.34 0.1  
RVES area (cm2) −2.9(−6.4
to0.7) 
−1.0(−4.4
to1.9) 
−0.4(−4to
0.5) 
−1.0(−2.8
to0.7) 
−0.8(−2.
5to1.7) 
−1.0(−2.8
to0.3) 
0.38 0.03  
RV fractional 
shortening area 
(%) 
6(−1to15) 5(0to13) 4(−4to11) 3(−3to8) −1(−11to
5) 
3(−3to13) 0.38 0.36  
Paired TR jet 41(46%) 60(80%) 45(48%) 46(50%) 47(55%) 61(66%)    
TR jet area (cm2) −0.6(−2.3
to0.8) 
−0.5(−2.2
to0.9) 
−0.4(−1.3
to1.4) 
−0.4(−1.7
to0.3) 
0.1(−1.2t
o1.1) 
−0.1(−1to
0.5) 
0.41 0.78  
RA diastolic area 
(cm2) 
−0.9(−7.7
to1.4) 
−1.3(−4.3
to0.9) 
−0.9(−3.9
to1.9) 
−0.6(−4.7
to1.2) 
−0.5(−2.
5to1.4) 
−1.1(−3.8
to1) 
0.56 0.39  
TR jet area/RA 
area (cm2) 
−4.5(−14.
9to5.6) 
−1.3(−11.
5to9.1) 
−2.2(−9.2
to11.7) 
−0.8(−14.
3to4.8) 
3.8(−4.2t
o12) 
2.8(−13.4
to10.8) 
0.32 0.2  
Paired TR gradient 29(33%) 28(37%) 32(34%) 16(17%) 22(26%) 20(22%)    
TR 
gradient<comma> 
mm Hg 
−8(−11.7t
o−3.4) 
−1.6(−10.
5to6.3) 
−0.4(−5.6
to3.7) 
−2.8(−6.1
to2.8) 
0(−9.2to
2.7) 
−5.1(−7.5
to−1.5) 
0.42 0.03  
 
p for interaction between CRT and TAPSE level from an analysis of variance model combining TAPSE levels 2/3. 
CRT = cardiac resynchronization therapy; other abbreviations as in Table 1. 
 
Table 3.           
        Multivariable Cox Regression Models With Baseline and 3-Month Data to Predict All-Cause Mortality 
Variables HR (95% 
CI) 
p 
Value 
       
NYHA functional class IV 2.16 (1.28–
3.63) 
0.004        
NT-proBNP<comma> 3 
months (pg/ml)* 
1.62 (1.41–
1.86) 
<0.00
1 
       
MR<comma> 3 months 
(cm2)* 
1.01 (1.00–
1.02) 
<0.00
1 
       
IVMD (ms) 0.98 (0.98–
0.99) 
<0.00
1 
       
CRT 0.57 (0.53–
0.99) 
0.04        
TAPSE<comma> 3 months 
(mm)* 
0.58 (0.40–
0.84) 
0.004        
TAPSE (mm)* by tertile         
T2 0.76 (0.56–
1.04) 
0.09        
T3 0.69 (0.50–
0.97) 
0.03        
Missing 0.97 (0.59–
1.58) 
0.91        
 
NT-proBNP transformed by natural logarithms. 
Q = quartile; other abbreviations as in Table 1. 
* 
3-month values imputed by last observation carried forward where baseline data missing. The TAPSE by tertile 
replaced TAPSE continuous (mm), adjusting for same covariates. Hazard ratio (HR) for missing TAPSE gives an 
indication of bias. 
 
